| 01st week of 2012 patent applcation highlights part 33 |
| Patent application number | Title | Published |
|---|
| 20120003201 | VAULT AGENTS FOR CHRONIC KIDNEY DISEASE - The invention relates to compositions of vault complexes containing cell adhesion inhibiting agents, such as a RGD-peptide, and methods of using the vault complexes in the treatment of diseases, such as chronic kidney disease. | 2012-01-05 |
| 20120003202 | CNS DELIVERY OF THERAPEUTIC AGENTS - The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme. | 2012-01-05 |
| 20120003203 | Compositions and Methods for Treating S. Pneumoniae Infection - The present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of infectious diseases. | 2012-01-05 |
| 20120003204 | COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION AND TREATMENT OF CANDER - The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by | 2012-01-05 |
| 20120003205 | PHARMACEUTICAL COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION OF LIVER DYSFUNCTION - The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for treating liver dysfunction which contains arazyme produced by | 2012-01-05 |
| 20120003206 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(═N—Z | 2012-01-05 |
| 20120003207 | METHODS AND COMPOSITIONS FOR MODULATING PROLINE LEVELS - Methods and compositions for modulating amino acid levels in a subject are provided herein. | 2012-01-05 |
| 20120003208 | COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT - The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided. | 2012-01-05 |
| 20120003209 | METHODS AND KITS USED IN IDENTIFYING GLIOBLASTOMA - The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of Akt1, Akt2, and Akt3. The methods and kits also allow prediction of disease outcome and staging of patients with regard to therapy. | 2012-01-05 |
| 20120003210 | NEONATAL Fc RECEPTOR (FcRn)- BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO - The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof. | 2012-01-05 |
| 20120003211 | IMMUNOGLOBULINS WITH REDUCED AGGREGATION - The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease. | 2012-01-05 |
| 20120003212 | ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8 ASSOCIATED DISORDERS - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 2012-01-05 |
| 20120003213 | Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity - The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule. | 2012-01-05 |
| 20120003214 | Binding Moieties Based On Shark IgNAR Domains - The present invention relates to immunoglobulin new antigen receptors (IgNARs) from fish and uses thereof. In particular, the present invention relates to modified IgNAR variable domains and to domains from members of the immunoglobulin superfamily that have been modified to include structural features derived from IgNAR variable domains. | 2012-01-05 |
| 20120003215 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT - The invention provides compounds of Formula I or Formula II: | 2012-01-05 |
| 20120003216 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2012-01-05 |
| 20120003217 | HERCEPTIN.RTM. ADUVANT THERAPY - The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®. | 2012-01-05 |
| 20120003218 | ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2012-01-05 |
| 20120003219 | Compositions and Methods to Treat Bone Related Disorders - The present invention relates to the use of modulators of the sclerostin:sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment, amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin:sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided. | 2012-01-05 |
| 20120003220 | B7-DC Variants - Variant costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein. | 2012-01-05 |
| 20120003221 | HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF - Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate. | 2012-01-05 |
| 20120003222 | FZD8 EXTRACELLULAR DOMAINS AND FZD8 EXTRACELLULAR DOMAIN FUSION MOLECULES AND TREATMENTS USING SAME - Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided. | 2012-01-05 |
| 20120003223 | RECOMBINANT FUSION PROTEIN AND POLYNUCLEOTIDE CONSTRUCT FOR IMMUNOTOXIN PRODUCTION - The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of | 2012-01-05 |
| 20120003224 | ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 - The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production. | 2012-01-05 |
| 20120003225 | AUTOANTIBODIES IN THE DETECTION AND TREATMENT OF CANCER - Methods, kits, and compositions for detecting and/or treating cancer based on detecting and/or administering an antibody, which can optionally be a bispecific antibody, having the immunoreaction characteristics of a cancer-associated autoantibody; an antigen for a cancer-associated autoantibody; or both an antibody having the immunoreaction characteristics of a cancer-associated autoantibody and an antigen for a cancer-associated autoantibody, in or to a subject in need thereof. | 2012-01-05 |
| 20120003226 | METHODS FOR TREATING OR PREVENTING IL-1BETA RELATED DISEASES - Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 2012-01-05 |
| 20120003227 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF VASCULAR INFLAMMATORY DISORDERS OR ENDOTHELIAL CELL DISORDERS - Disclosed herein are methods for treating a vascular inflammatory disorder or endothelial cell disorder using inhibitor compounds that inhibit the expression or biological activity of Tie-1, Tie-1 endodomain, thrombin, VEGFR2, VEGFR2 endodomain, EphA2, and any of the cytokines or kinases that are upregulated by activation of Tie-1 or thrombin, as provided herein. Also disclosed are the use of combinations of inhibitor compounds or the use of an eNOS activator compound in combination with any one or more of the inhibitor compounds. Also disclosed are methods for inhibiting the pro-coagulant activity of thrombin using a Tie-1 or Tie-1 endodomain inhibitor compound or an EphA2 inhibitor compound. Methods for diagnosing and monitoring vascular inflammatory disorders or endothelial cell disorders that include the measurement of any of the polypeptides or nucleic acid molecules of the invention are also disclosed. | 2012-01-05 |
| 20120003228 | METHODS FOR PREDICTING AUTOIMMUNE DISEASE RISK - The invention relates to means and methods for determining whether a subject is at high or low risk of autoimmune disease progression by determining the CD8 or CD4 cell subtype of the subject. Autoimmune diseases of particular interest include vasculitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. The invention also relates to means and methods for determining the CD8 or CD4 cell subtype of a subject, e.g. for predicting responses to infection, vaccination and/or transplantation. | 2012-01-05 |
| 20120003229 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY - The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin α | 2012-01-05 |
| 20120003230 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER - A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition. | 2012-01-05 |
| 20120003231 | CELL SURFACE MOLECULE MEDIATING CELL ADHESION AND SIGNAL TRANSMISSION - Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases. | 2012-01-05 |
| 20120003232 | USE OF ANTIBODIES FOR THE VACCINATION AGAINST CANCER - Described is the use of antibodies which are directed against human cellular membrane antigens for the vaccination against cancer diseases. | 2012-01-05 |
| 20120003233 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR - The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed. | 2012-01-05 |
| 20120003234 | Osteoarthritis treatment - The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models. | 2012-01-05 |
| 20120003235 | ANTI-LYMPHOTOXIN ANTIBODIES - The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LTβR signaling are also provided. | 2012-01-05 |
| 20120003236 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor. | 2012-01-05 |
| 20120003237 | WISE BINDING AGENTS AND EPITOPES - The present invention relates to binding agents for WISE, and includes for their manufacture and use. | 2012-01-05 |
| 20120003238 | Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (I) - Some coxsackie B viruses have been found to have a protective effect on type 1 diabetes, while others increase the risk of the disease. This opens up new therapeutic implications in the form of vaccines. The protective viruses CBV3, CBV4, CBV5 and CBV6 may be used in live attenuated vaccines for preventing or treating type 1 diabetes. They may also be used for inducing an immune response against risk viruses like CBV1, and for eliminating the diabetogenic effect of the risk viruses. Type 1 diabetes may be prevented especially by vaccinating with live attenuated protective viruses CBV3, CBV4, CVB5 and CBV6, and further with inactivated diabetogenic/risk virus CBV1, components thereof or antibodies thereto. | 2012-01-05 |
| 20120003239 | Enterovirus Vaccines for Preventing and Treating Type 1 Diabetes (II) - New enteroviruses associated with type 1 diabetes have been found, which opens up new therapeutic and diagnostic implications. A vaccine against at least one enterovirus selected from coxsackie A virus CAV4, CAV5, CAVE and echovirus 18 is provided for use in preventing or treating type 1 diabetes. A diagnostic assay for predicting the risk of contracting type 1 diabetes based on the determination of said enteroviruses is also provided. | 2012-01-05 |
| 20120003240 | Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (III) - Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic. | 2012-01-05 |
| 20120003241 | VACCINE AGAINST BOTULISM - The invention relates to novel DNA and protein vaccines against | 2012-01-05 |
| 20120003242 | MODULATING PDX-1 WITH PCIF1, METHODS AND USES THEREOF - This invention relates to PCIF1 and its use as a target for the improvement of pancreatic islet β cell mass and function in diabetes. Specifically, the invention relates to the use of compounds capable of modulating the expression or function of PCIF1 and their effect on the function of Pdx-1. | 2012-01-05 |
| 20120003243 | YEAST ECTOPICALLY EXPRESSING ABNORMALLY PROCESSED PROTEINS AND USES THEREFOR - Disclosed are yeast ectopically expressing abnormally processed proteins and methods of screening to identify compounds that modulate the function of such abnormally processed proteins in yeast. Compounds identified by such screens can be used to treat or prevent diseases associated with abnormally processed proteins or protein misfolding. Such diseases include Parkinson's Disease, Parkinson's Disease with accompanying dementia, Lewy body dementia, Alzheimer's disease with Parkinsonism, and multiple system atrophy. | 2012-01-05 |
| 20120003244 | METHODS FOR APCDD1 MEDIATED REGULATION OF HAIR GROWTH AND PIGMENTATION AND MUTANTS THEREOF - The invention provides for methods for controlling hair growth by administering an APCDD1 modulating compound to a subject. The invention further provides for a method for screening compounds that bind to and modulate APCDD1. | 2012-01-05 |
| 20120003245 | ANTI-COBRA TOXIN ANTIBODY FRAGMENTS AND METHOD OF PRODUCING A VHH LIBRARY - A method of constructing a V | 2012-01-05 |
| 20120003246 | Novel composition and methods for the treatment of psoriasis - The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis. | 2012-01-05 |
| 20120003247 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-01-05 |
| 20120003248 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-01-05 |
| 20120003249 | IMMUNO-MOLECULES CONTAINING VIRAL PROTEINS, COMPOSITIONS THEREOF AND METHODS OF USING - An immuno-molecule which comprises a soluble human MHC class I effector domain; and an antibody targeting domain which is linked to the soluble human MHC class I effector domain, methods of making same and uses thereof. | 2012-01-05 |
| 20120003250 | PHARMACEUTICAL COMPOSITION WITH IMMUNOMODULATING FUNCTION - A pharmaceutical composition with an immunomodulating function is provided, including an extract of | 2012-01-05 |
| 20120003251 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epi topes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 2012-01-05 |
| 20120003252 | ISOFORMS OF HUMAN SOMATOSTATIN RECEPTOR TYPE 5 PRODUCED BY ALTERNATIVE PROCESSING AND OLIGO-NUCLEOTIDE PAIRS FOR DETECTION THEREOF BY PCR - The present invention concerns two human nucleic acids comprising sequences which code two novel isoforms of human somatostatin receptor type 5 produced by alternative adjustment, called sst5B and sst5C and with possible uses in tumoral processes. Additionally, the invention concerns oligonucleotide pairs used for the differential detection of said isoforms by means of the PCR technique in different tissues. | 2012-01-05 |
| 20120003253 | C1ORF59 PEPTIDES AND VACCINES INCLUDING THE SAME - The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 43 or immunologically active fragments thereof, which bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents and compositions of this invention may be used for treating cancer or tumor. | 2012-01-05 |
| 20120003254 | Breast Cancer Vaccine - Compositions and methods for immunization against human breast cancer are disclosed. A breast cancer vaccine comprises an immunogenic polypeptide comprising human α-lactalbumin. | 2012-01-05 |
| 20120003255 | FLAVIVIRUS HOST-RANGE MUTATIONS AND USES THEREOF - Methods and compositions concerning mutant flaviviruses with host-range phenotypes are provided. Nucleotide sequences that encode mutant flavivirus proteins are also provided. In certain aspects, viruses comprising these sequences display reduced replication in mammalian cells. In further aspects of the invention, flavivirus vaccine compositions and methods for vaccination against flavivirus infection are provided. | 2012-01-05 |
| 20120003256 | TUBERCULOSIS ANTIGENS, IMMUNOGENIC COMPOSITIONS, DIAGNOSTICS AND METHODS RELATED TO THE SAME - Provided herein are Mtb polynucleotides, recombinant Mtb peptides and polypeptides, immunogenic Mtb antigens, and Mtb antibodies. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides kits comprising Mtb polynucleotides, Mtb polypeptides, Mtb antibodies, and combinations thereof. | 2012-01-05 |
| 20120003257 | RECOMBINANT AVIAN INFECTIOUS CORYZA VACCINE AND PROCESS FOR PREPARING SAME - A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of constructing | 2012-01-05 |
| 20120003258 | MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against | 2012-01-05 |
| 20120003259 | MOLECULE - We describe an Fve polypeptide being a fragment, homologue, variant or derivative of Fve protein, which comprises at least one biological activity of Fve protein. uses of such a polypeptide, etc, and nucleic acids encoding these, in the treatment and prevention of allergy and cancer are also disclosed. | 2012-01-05 |
| 20120003260 | Solid-Phase and Solution-Phase Synthesis of Glycosylphosphatidylinositol Glycans - One aspect of the present invention relates to solution-phase approaches to GPI synthesis. Another aspect of the present invention relates to key building blocks, and syntheses thereof, useful for GPI assembly. Yet another aspect of the invention relates to an automated method for the synthesis of GPIs and fragments thereof. | 2012-01-05 |
| 20120003261 | DIGOXIN-LIKE FUNGAL GLYCOSIDE WITH CYTOTOXIC PROPERTIES: NOVEL ASSAY AND APPLICATIONS - The present invention provides methods of isolating cytotoxic metabolites from a fungus, and specific metabolites obtained from such methods. The present invention also provides methods of controlling fungal diseases in plants by treating the plants with cytotoxic metabolites as well as methods of treating cardiac arrhythmia in organisms in need of such treatment by administering the above-noted metabolites to such organisms. | 2012-01-05 |
| 20120003262 | ANTICANCER HEALTH FOOD CONTAINING PHELLINUS LINTEUS AND VEGETABLE WORMS - Disclosed is a health food containing extracts of | 2012-01-05 |
| 20120003263 | RECOMBINANT RACCOON POX VIRUS VACCINE AGAINST HIGHLY PATHOGENIC AVIAN INFLUENZA - Vaccines comprising one or more recombinant raccoon pox viruses and methods of using those vaccines to immunize avians. | 2012-01-05 |
| 20120003264 | CDNA Corresponding to the Antigenome of Nonsegmented Negative Stranded RNA Viruses and Process for the Production of Such Viruses - The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae. | 2012-01-05 |
| 20120003265 | IMMUNOGENIC COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO HIV - The invention relates to immunogenic compositions for inducing an immune response to HIV comprising combinations of two, three, or four plasmids, where each plasmid is expressing a defined antigen, which may be a single antigen or a fusion of two or three antigens. | 2012-01-05 |
| 20120003266 | VIRUS LIKE PARTICLE COMPOSITIONS AND METHODS OF USE - The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases. | 2012-01-05 |
| 20120003267 | Therapeutic Agents - A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease. | 2012-01-05 |
| 20120003268 | SYNERGISTIC COMBINATION AND METHOD THEREOF - A method for the treatment of myeloma and thymoma by administering a therapeutically effective dose of | 2012-01-05 |
| 20120003269 | Compositions Produced Using Enteric Pathogens and Methods of Use - The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such | 2012-01-05 |
| 20120003270 | 6-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND USES THEREOF - The present invention relates to 6-substituted isoflavonoid compounds and compositions comprising same. The invention further relates to the use of 6-substituted isoflavonoid compounds for the treatment of various diseases and conditions. | 2012-01-05 |
| 20120003271 | POLYMER BLENDS - A biocompatible polymer mixture for use as a matrix for cellular attachment includes a mixture of at least two polymers selected from the group consisting of: chitosan (CS), polyethylenimine (PEI), poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA), poly(2-hydroxy ethyl methacrylate) (PHEMA), poly(ε-caprolactone) (PCL), poly(vinyl acetate) (PVAc), poly(ethylene oxide) (PEO), poly[(R)-3-hydroxybutyric acid)] (PHB), cellulose acetate (CA), poly(lactide-co-glycolide) (PLGA) and poly(N-isopropylacrylamide) (PNIPAM). Implants making use of the polymer mixtures can support cell attachment, growth and differentiation, and tissue regeneration in vivo. | 2012-01-05 |
| 20120003272 | CONCRETE SCAFFOLD CONTAINING BMP-2 AND MADE OF BONE POWDER AND FIBRIN GLUE - The present invention relates to a bone-regenerating scaffold containing bone morphogenic protein 2 (BMP-2), and more particularly, to a bone-regenerating scaffold which is made of a mixture of fibrin glue and bone powder, the interior of which has a plurality of pores for accommodating bone growth factors, and which has a predetermined concrete shape. The bone-regenerating scaffold of the present invention contains BMP-2 as the above-mentioned bone growth factor. | 2012-01-05 |
| 20120003273 | SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS - The present invention relates to novel substituted benzfurochromenes and related compounds having the general formula (I), salts and chiral, achiral derivatives thereof; wherein R | 2012-01-05 |
| 20120003274 | ORAL SUSTAINED RELEASE ANTIDEPRESSANT FORMULATION - Pharmaceutical presentations or phenoxathiin-based MAO-A inhibitors are disclosed whereby the MAO receptors are capable of sustained release in the digestive tract. Particular phenoxathiin-based MAO-A inhibitors include those of the following formula: wherein n is 0, 1 or 2; R | 2012-01-05 |
| 20120003275 | Compositions and Methods for the Treatment of Ophthalmic Disease - Compositions and methods of treating ocular disorders comprising CXCR4 inhibitory compositions. | 2012-01-05 |
| 20120003276 | DERMAL MICRO-ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME - Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Other embodiments are described and claimed. | 2012-01-05 |
| 20120003277 | NANOEMULSION VACCINES - The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the invention find use in, among other things, clinical (e.g., therapeutic and preventative medicine (e.g., vaccination)) and research applications. | 2012-01-05 |
| 20120003278 | SINGLE-WALLED CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO - The present invention includes single-walled carbon nanotube compositions for the delivery of bioactive agents and methods of making such single-walled carbon nanotube compositions. | 2012-01-05 |
| 20120003279 | Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided. | 2012-01-05 |
| 20120003280 | CERAMIC/STRUCTURAL PROTEIN COMPOSITES AND METHOD OF PREPARATION THEREOF - Ceramic/structural protein composites and methods of preparation are disclosed, including coatings and films. Ceramic/structural protein coatings can be fabricated on the surface of substrates, including the surface of implantable medical devices. | 2012-01-05 |
| 20120003281 | USE OF AN ACARICIDAL POWDER - Use of a powder comprising more than 40% by weight of sodium bicarbonate, for its acaricidal effects in the storage of cereals. | 2012-01-05 |
| 20120003282 | PHARMACEUTICAL COMPOSITIONS OF DEXTRAN POLYMER DERIVATIVES - Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof. | 2012-01-05 |
| 20120003283 | Injectable Biomaterials - Injectable biomaterial compositions formed from tropoelastin for tissue repair and restoration. The compositions include a coalescence-controlling agent in the form of a polysaccharide or polysaccharide derivative, in an amount effective for providing the substance with the properties of flow, enabling injection. | 2012-01-05 |
| 20120003284 | COSMETIC METHOD FOR TREATING HUMAN PERSPIRATION USING PARTICLES OF AN EXPANDED AMORPHOUS MINERAL MATERIAL; COMPOSITIONS - The invention relates to a cosmetic method for treating perspiration and, optionally, the body odours related to human perspiration, in particular underarm odours, an effective amount of particles of an expanded amorphous mineral material or of a composition containing said particles, and more particularly containing expanded perlite particles. The subject of the present invention is also a cosmetic method for treating perspiration and, optionally, the body odours related to human perspiration, in particular underarm odours, an effective amount of particles of a composition containing, in a cosmetically acceptable carrier, at least said particles and at least one antiperspirant salt or complex. The subject of the present invention is also a composition containing, in a cosmetically acceptable carrier, at least said particles and at least one antiperspirant salt or complex. The subject of the present invention is also an anhydrous solid composition in the form of a stick, characterized in that it comprises, in a cosmetically acceptable carrier: (i) more than 1% by weight, relative to the total weight of the composition, of expanded mineral particles as defined above; and (ii) at least one fatty phase comprising at least one volatile oil and/or at least one non-volatile oil and a structuring agent. | 2012-01-05 |
| 20120003285 | METHOD FOR MANUFACTURING CAPSULE SERIES, AND RELATED CAPSULE SERIES - A method includes separately conveying a first liquid solution ( | 2012-01-05 |
| 20120003286 | COSMETIC CANDLE - A cosmetic candle comprising tiny grains embedded therein. The grains impart a mechanical property that can be exploited for scrubbing skin to peel off old or dead tissue with a concomitant massaging of molten waxes into the skin. Crushed pits and seeds of olives, apricots, peaches, citrus fruits and/or plums are natural products that can be used as grains in embodiments of the invention. In addition, solid salt grains, such as natural salts from the Dead Sea, or sugar grains, may also be used to that effect. | 2012-01-05 |
| 20120003287 | SELF-DISPERSIBLE COATED METAL OXIDE POWDER, AND PROCESS FOR PRODUCTION AND USE - Disclosed is a composition having a substrate comprising metal oxide particles. The substrate has a coating thereon that includes an organic dispersant present in a amount that renders the substrate self-dispersible. Also disclosed is a composition, such as a cosmetic composition, that includes that self-dispersible coated substrate, and a process that includes coating a particulate metal oxide with an organic dispersant to render the metal oxide self-dispersible. | 2012-01-05 |
| 20120003288 | DISPERSION COMPOSITION AND METHOD FOR MANUFACTURING DISPERSION COMPOSITION - The present invention provides: a dispersion composition including a poorly water-soluble polyphenol compound, an emulsifier including a sucrose fatty acid ester, and a water-soluble polymer, in which a content of a polyglycerin fatty acid ester in the composition is 0, or 0.1 or fewer times a total mass of the sucrose fatty acid ester in the composition, and a particle size of the dispersed particles including the poorly water-soluble polyphenol is 200 nm or smaller; and a method for manufacturing the dispersion composition, the method including an oil phase preparation process in which an oil phase is prepared by dissolving one or more oil phase components including the poorly water-soluble polyphenol in a good solvent for the poorly water-soluble polyphenol compound, and a mixing process in which the obtained oil phase and a phase of a poor solvent for the poorly water-soluble polyphenol compound are mixed to obtain the dispersion composition which includes the poorly water-soluble polyphenol compound and includes dispersed particles having an average volume particle size of 200 nm or smaller. | 2012-01-05 |
| 20120003289 | WASHING AID HAVING AN ANTIBACTERIAL EFFECT - The present invention is an auxiliary washing aid comprising a textile substrate coated or otherwise impregnated with a composition comprising elementary silver and/or a silver compound, non-neutralized fatty acid, and hydrogen peroxide. | 2012-01-05 |
| 20120003290 | METHOD FOR REDUCING PAIN - The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil. | 2012-01-05 |
| 20120003291 | NANOBEAD RELEASING MEDICAL DEVICES - Medical devices comprising nanobeads encapsulating one or more bioactive agents and methods of use thereof are provided. | 2012-01-05 |
| 20120003292 | ANTI-INFLAMMATORY DISSOLVABLE FILM - Provided, among other things, is a slowly dissolvable film comprising: herbal bioactive agent(s); and polymer(s), dissolvable in the aggregate, wherein the film becomes adhesive as it is placed against a mucosal surface and begins to absorb moisture therefrom. | 2012-01-05 |
| 20120003293 | NITRIC OXIDE-RELEASING DRESSINGS - A wound dressing comprising nitric oxide gas producing component. | 2012-01-05 |
| 20120003294 | FIXED RATIO CAMPTOTHECENS/PLATINUM AGENTS - Compositions which comprise liposomes having controlled release of a platinum agent are useful in achieving enhanced therapeutic effects particularly when these drugs are administered in combination with other therapeutic agents. | 2012-01-05 |
| 20120003295 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS - The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc. | 2012-01-05 |
| 20120003296 | NEW METHODS OF TREATING DRY EYE SYNDROME - The invention relates to a method of insulin eye drops for treating dry eye syndrome due to any and all etiological factors (Keratoconjunctivitis sicca), including Sjogren's syndrome, Meibomian gland dysfunction (MGD) and other glandular malfunction in the eye lids, lacrimal glands, cornea, conjunctiva, and exposed scleral surface of the eye. It is treated with Insulin and/or IGF-I with or without known anti-dry eye syndrome therapeutic, pharmaceutical, biochemical and biological agents or compounds. | 2012-01-05 |
| 20120003297 | COMPOSITIONS AND METHODS FOR TREATING LYMPHOMA - This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma. | 2012-01-05 |
| 20120003298 | METHODS FOR INDUCING AN IMMUNE RESPONSE - Provided in some embodiments are methods for inducing an antigen-specific immune response in a subject, comprising administering a compound having a structure according to Formula A or Formula B: | 2012-01-05 |
| 20120003299 | NOVEL HSP90-TARGETED ANTI-CANCER CHIMERIC PEPTIDE - Disclosed is a substance which is not accumulated stably in cells, does not cause the dysfunction of normal cells, and so on, and therefore can be used as an anti-cancer agent or in a DDS without having any adverse side effects. It is found that Hsp90 alone cannot exhibit its function as a chaperone in assisting the refolding of a protein such as survivin, but can exhibit this function when Hop (which is one of the partner proteins of Hsp90) binds to Hsp90. Thus, specifically disclosed herein is a chimeric peptide comprising of an Hsp90 TPR domain binding peptide and a cell-penetrating peptide. | 2012-01-05 |
| 20120003300 | Composition Comprising Vascular Endothelial Growth Factor (VEGF) for the Treatment of Hair Loss - A composition to treat hair loss and enhance hair growth and condition. The composition comprises: i) one or more of VEGF, a VEGF biomimetic peptide, and/or a VEGFR2 receptor agonist; ii) ciclopirox olamine; and iii) a pharmaceutically acceptable carrier. | 2012-01-05 |
